Adrenal function recovery after durable oral corticosteroid sparing with benralizumab in the PONENTE study

• Autor(a) principal: Menzies-Gow, Andrew
• Data de Publicação: 2022
• Outros Autores: Gurnell, Mark, Heaney, Liam G., Corren, Jonathan, Bel, Elisabeth H., Maspero, Jorge, Harrison, Timothy, Jackson, David J., Price, David, Lugogo, Njira, Kreindler, James, Burden, Annie, de Giorgio-Miller, Alex, Faison, Sarai, Padilla, Kelly, Martin, Ubaldo J., Gil, Esther Garcia, Ardusso, Ledit, Bazerque, Rocio Fernandez, Doreski, Pablo Alexis Christian, Elias, Pedro Carlos, Gattolin, Gabriel, Medina, Andrea Cintia, Ruiz, Xavier Bocca, Salvado, Alejandro, Del Olmo Sansone, Ricardo Alfonso, Wehbe, Luis, Verra, Fernando José Bartolomé, Brusselle, Guy, Pilette, Charles, Martinot, Jean-Benoît, Antila, Martti Anton, Blanco, Daniela Cavalet, Cerci, Alcindo, Cunha, Thulio Marquez, Fiss, Elie, Franza, Luciene, Machado, Adelmir Souza, De Mattos, Waldo Luis Leite Dias, Grava, Sergio, Minamoto, Suzana Erico Tanni [UNESP], De Oliveira, Carlos Alberto, Cheema, Amarjit S., Dorscheid, Delbert, Fera, Tharwat A.E., Gagnon, Remi, Philteos, George, Sussman, Gordon, Yang, William Ho-Ching, Aguilar, Carlos Dario, Jaller, Rodolfo, Jazime, Myrna Liliana, Serrano, Francisco Orlando, Vanegas, Ana Catalina, Vargas, Leslie Katherine, Villegas, Maria Fernanda, Hilberg, Ole, Nielsen, Henning Bay, Nielsen, Jakob, Weinreich, Ulla Møller, Ulrik, Charlotte Suppli, Adam, Sylvain Marchand, Deslee, Gaëtan, Pegliasco, Hervé, Pradelli, Johana, Roux, Pauline-Marie, Russier, Maud, Deckelmann, Regina, Eich, Andreas, Forster, Andreas, Herth, Felix, Kirschner, Joachim, Kirsten, Anne-Marie, Schuhmann, Maren, Schultz, Thomas K., Ludwig-Sengpiel, Andrea, Teber, Ishak, Zimmermann, Gregor S., Almerigogna, Fabio, Celi, Alessandro, Paggiaro, Pierluigi, D'Amato, Maria, Palange, Paolo, Pirina, Pietro, Spanevello, Antonio, Colin, Dante Daniel Hernandez, Hernández, Amado Ramírez, García, Edgar Alejandro Reyes, Gonzalez, Efrain Montaño, Terrones, Ricardo Alberto Ramirez, Javier, Ruth Cerino, Suarez, Juan Francisco Rubio, Cheimihska, Marta, Cudzik, Krzysztof, Olech-Cudzik, Anna, Filipek, Krzysztof, Goliński, Łukasz, Kwaśniewski, Artur, Mądra-Rogacka, Danuta, Mróz, Robert, Nittner-Marszalska, Marita, Pawlukiewicz, Maigorzata, Lekarska, Prywatna Praktyka, Pioszczuk, Anna, Springer, Ewa, Świderska, Anna, Żurowska-Gębala, Małgorzata, Emelyanov, Alexander Viktorovich, Kurbacheva, Oksana, Odegova, Alla, Peskov, Andrey, Petrov, Dmitriy Vladimirovich, Rubanik, Tamara Vsevolodovna, Vasilev, Maksim, Vershinina, Maria, Barcala, Francisco Javier González, Blanco, Vanessa Riveiro, Fernández, Antonio Manuel Pérez, Fernández, Coral González, García, José María Ignacio, Muñoz, Aurelio Victor Arnedillo, Ramos, Concepción Cañete, Sanz, Carlos Colás, Bjermer, Leif, Chen, Chung-Yu, Fang, Wen-Feng, Hang, Liang-Wen, Hsu, Jeng-Yuan, Kuo, Han-Pin, Lee, Kang-Yun, Shen, Sheng-Yeh, Sheu, Chau-Chyun, Gore, Robin, Saralaya, Dinesh, Alpizar, Sady A., Bansal, Sandeep, Ismail, Hummayun, Kaelin, Thomas D., Koura, Firas, Lee, Mitchell Douglas, Maddipati, Veeranna, Malur, Anagha, McEvoy, Charlene E., Mehta, Hemalini, Mohan, Arjun, Moore, Wendy C., Krings, Jeffery, Pippins, Anna, Deaton, Isaac, Hmieleski, Bob, Field, Paige, Reibman, Joan, Siri, Dareen D., Sumino, Kaharu, Swenson, Colin, Tilley, Stephen Lloyd, Villareal, Manuel
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UNESP
• Texto Completo: http://dx.doi.org/10.1183/13993003.03226-2021; http://hdl.handle.net/11449/246525

Background Oral corticosteroid (OCS) dependence among patients with severe eosinophilic asthma can cause adverse outcomes, including adrenal insufficiency. PONENTE's OCS reduction phase showed that, following benralizumab initiation, 91.5% of patients eliminated corticosteroids or achieved a final dosage ≤5 mg·day-1 (median (range) 0.0 (0.0-40.0) mg). Methods The maintenance phase assessed the durability of corticosteroid reduction and further adrenal function recovery. For ~6 months, patients continued benralizumab 30 mg every 8 weeks without corticosteroids or with the final dosage achieved during the reduction phase. Investigators could prescribe corticosteroids for asthma exacerbations or increase daily dosages for asthma control deteriorations. Outcomes included changes in daily OCS dosage, Asthma Control Questionnaire (ACQ)-6 and St George's Respiratory Questionnaire (SGRQ), as well as adrenal status, asthma exacerbations and adverse events. Results 598 patients entered PONENTE; 563 (94.1%) completed the reduction phase and entered the maintenance phase. From the end of reduction to the end of maintenance, the median (range) OCS dosage was unchanged (0.0 (0.0-40.0) mg), 3.2% (n=18/563) of patients experienced daily dosage increases, the mean ACQ-6 score decreased from 1.26 to 1.18 and 84.5% (n=476/563) of patients were exacerbation free. The mean SGRQ improvement (-19.65 points) from baseline to the end of maintenance indicated substantial quality-of-life improvements. Of patients entering the maintenance phase with adrenal insufficiency, 32.4% (n=104/321) demonstrated an improvement in adrenal function. Adverse events were consistent with previous reports. Conclusions Most patients successfully maintained maximal OCS reduction while achieving improved asthma control with few exacerbations and maintaining or recovering adrenal function.